Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation

Circulation

Volumn 125, Issue 2, 2012, Pages 216-225

  Igarashi, Tomonori ^a   Finet, J Emanuel ^a   Takeuchi, Ayano ^b   Fujino, Yoshihisa ^c   Strom, Maria ^a   Greener, Ian D ^a   Rosenbaum, David S ^a   Donahue, J Kevin ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

atrial fibrillation; connexin; gap junction protein; gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CONNEXIN 40; CONNEXIN 43;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE TRANSFER; HEART ATRIUM CONDUCTION; HEART ATRIUM CONDUCTION VELOCITY; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; SWINE; TOXICITY; VIRAL GENE THERAPY;

ANIMALS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CONNEXIN 43; CONNEXINS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEART CONDUCTION SYSTEM; SWINE; TREATMENT OUTCOME;

EID: 84856087307     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.053272     Document Type: Article

References (43)

1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125. (Pubitemid 44420743)
2. Corley S, Epstein A, DiMarco J, Domanski M, Geller N, Greene H, Josephson M, Kellen J, Klein R, Krahn A, Mickel M, Mitchell L, Nelson J, Rosenberg Y, Schron E, Shemanski L, Waldo A, Wyse D, AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation. 2004;109:1509-1513. (Pubitemid 38420179)
3. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008;127:299-306.
4. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-38.
5. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: Can mechanistic insights be used to improve AF management? Cardiovasc Res. 2002;54:347-360. (Pubitemid 34327914)
6. Roberts JD, Gollob MH. Impact of genetic discoveries on the classification of lone atrial fibrillation. J Am Coll Cardiol. 2010;55:705-712.
7. Atienza F, Almendral J, Moreno J, Vaidyanathan R, Talkachou A, Kalifa J, Arenal A, Villacastan J, Torrecilla E, Sanchez A, Ploutz-Snyder R, Jalife J, Berenfeld O. Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: Evidence for a reentrant mechanism. Circulation. 2006;114:2434-2442. (Pubitemid 44901515)
8. Amit G, Kikuchi K, Greener ID, Yang L, Novack V, Donahue JK. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010;121:2263-2270.
9. Pederson O, Bagger H, Keller N, Marchant B, Kober L, Torp-Peterson C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) substudy. Circulation. 2001;104:292-296. (Pubitemid 32666950)
10. Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev. 2004;84:431-488. (Pubitemid 38365490)
11. Davis LM, Kanter HL, Beyer EC, Saffitz JE. Distinct gap junction protein phenotypes in cardiac tissues with disparate conduction properties. J Am Coll Cardiol. 1994;24:1124-1132. (Pubitemid 24306428)
12. Kikuchi K, McDonald AD, Sasano T, Donahue JK. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation. 2005;111:264-270. (Pubitemid 40165331)
13. Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med. 2006;12: 1256-1258. (Pubitemid 44706927)
14. Bauer A, McDonald AD, Donahue JK. Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res. 2004;61:764-770. (Pubitemid 38249475)
15. Bauer A, McDonald AD, Nasir K, Peller L, Rade JJ, Miller JM, Heldman AW, Donahue JK. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation. 2004;110:3115-3120. (Pubitemid 39492007)
16. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res. 2002; 54:361-379. (Pubitemid 34327915)
17. Schotten U, Ausma J, Stellbrink C, Sabatschus I, Vogel M, Frechen D, Schoendube F, Hanrath P, Allessie M. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation. 2001;103:691-698. (Pubitemid 32144198)
18. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Borgers M. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997;96:3157-3163. (Pubitemid 27500121)
19. van der Velden H, Ausma J, Rook M, Hellemons A, van Veen T, Allessie M, Jongsma H. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res. 2000;46:476-486. (Pubitemid 30319333)
20. van der Velden H, van Kempen M, Wijffels M, van Zijverden M, Groenewegen W, Allessie M, Jongsma H. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophys. 1998;9:596-607. (Pubitemid 128721719)
21. Ryu K, Li L, Khrestian CM, Matsumoto N, Sahadevan J, Ruehr ML, Van Wagoner DR, Efimov IR, Waldo AL. Effects of sterile pericarditis on connexins 40 and 43 in the atria: Correlation with abnormal conduction and atrial arrhythmias. Am J Physiol Heart Circ Physiol. 2007;293: H1231-H1241. (Pubitemid 47254226)
22. Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation. 1997;96:4027-4035.
23. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, Nattel S. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res. 2009;105:1213-1222.
24. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs: Electrophysiological remodeling. Circulation. 1996;94:2953-2960. (Pubitemid 26411765)
25. Li D, Fareh S, Leung T, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation. 1999; 100:87-95. (Pubitemid 29297945)
26. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, Bai D. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med. 2006;354:2677-2688.
27. Thibodeau IL, Xu J, Li Q, Liu G, Lam K, Veinot JP, Birnie DH, Jones DL, Krahn AD, Lemery R, Nicholson BJ, Gollob MH. Paradigm of genetic mosaicism and lone atrial fibrillation: Physiological characterization of a connexin 43-deletion mutant identified from atrial tissue. Circulation. 2010;122:236-244.
28. Rucker-Martin C, Milliez P, Tan S, Decrouy X, Recouvreur M, Vranckx R, Delcayre C, Renaud JF, Dunia I, Segretain D, Hatem SN. Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res. 2006;72:69-79. (Pubitemid 44310634)
29. Nao T, Ohkusa T, Hisamatsu Y, Inoue N, Matsumoto T, Yamada J, Shimizu A, Yoshiga Y, Yamagata T. Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. Am J Cardiol. 2003;91:678-683. (Pubitemid 36287457)
30. Gaborit N, Steenman M, Lamirault G, Le Meur N, Le Bouter S, Lande G, Leger J, Charpentier F, Christ T, Dobrev D, Escande D, Nattel S, Demolombe S. Human atrial ion channel and transporter subunit gene- expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation. 2005;112:471-481. (Pubitemid 41060786)
31. Wetzel U, Boldt A, Lauschke J, Weigl J, Schirdewahn P, Dorszewski A, Doll N, Hindricks G, Dhein S, Kottkamp H. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart. 2005;91:166-170.
32. Fukaya H, Niwano S, Satoh D, Masaki Y, Niwano H, Kojima J, Moriguchi M, Izumi T. Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model. Circ J. 2008;72: 318-326. (Pubitemid 351413375)
33. Elvan A, Huang XD, Pressler ML, Zipes DP. Radiofrequency catheter ablation of the atria eliminates pacing-induced sustained atrial fibrillation and reduces connexin 43 in dogs. Circulation. 1997;96:1675-85. (Pubitemid 27375369)
34. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus H, Bauer A. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 2011;92:218-225.
35. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation. 2007;115:310-318. (Pubitemid 46151658)
36. Guerra JM, Everett TH, Lee KW, Wilson E, Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation. 2006;114:110-118. (Pubitemid 44420742)
37. Dhein S, Hagen A, Jozwiak J, Dietze A, Garbade J, Barten M, Kostelka M, Mohr FW. Improving cardiac gap junction communication as a new antiarrhythmic mechanism: The action of antiarrhythmic peptides. Naunyn Schmiedebergs Arch Pharmacol. 2010;381:221-234.
38. Thomas SA, Schuessler RB, Berul CI, Beardslee MA, Beyer EC, Mendelsohn ME, Saffitz JE. Disparate effects of deficient expression of connexin43 on atrial and ventricular conduction: Evidence for chamberspecific molecular determinants of conduction. Circulation. 1998;97: 686-691. (Pubitemid 28090963)
39. Beauchamp P, Yamada K, Baertschi A, Green K, Kanter E, Saffitz J, Kleber A. Relative contributions of connexins 40 and 43 to atrial impulse propagation in synthetic strands of neonatal and fetal murine cardiomyocytes. Circ Res. 2006;99:1216-1224. (Pubitemid 44808658)
40. Leaf DE, Feig JE, Vasquez C, Riva PL, Yu C, Lader JM, Kontogeorgis A, Baron EL, Peters NS, Fisher EA, Gutstein DE, Morley GE. Connexin40 imparts conduction heterogeneity to atrial tissue. Circ Res. 2008;103:1001-1008.
41. Verheule S, van Batenburg CA, Coenjaerts FE, Kirchhoff S, Willecke K, Jongsma HJ. Cardiac conduction abnormalities in mice lacking the gap junction protein connexin40. J Cardiovasc Electrophysiol. 1999;10: 1380-1389. (Pubitemid 29468578)
42. Cottrell GT, Wu Y, Burt JM. Cx40 and Cx43 expression ratio influences heteromeric/heterotypic gap junction channel properties. Am J Physiol Cell Physiol. 2002;282:C1469-C1482. (Pubitemid 34663096)
43. Cottrell GT, Burt JM. Heterotypic gap junction channel formation between heteromeric and homomeric Cx40 and Cx43 connexons. Am J Physiol Cell Physiol. 2001;281:C1559-C1567.